2269 Stock Overview
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People’s Republic of China, North America, Europe, and internationally.
WuXi Biologics (Cayman) Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$71.80|
|52 Week High||HK$143.00|
|52 Week Low||HK$40.30|
|1 Month Change||25.97%|
|3 Month Change||3.24%|
|1 Year Change||-47.97%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-6.63%|
Recent News & Updates
|2269||HK Life Sciences||HK Market|
Return vs Industry: 2269 underperformed the Hong Kong Life Sciences industry which returned -46.7% over the past year.
Return vs Market: 2269 underperformed the Hong Kong Market which returned -20.3% over the past year.
|2269 Average Weekly Movement||9.9%|
|Life Sciences Industry Average Movement||8.7%|
|Market Average Movement||6.9%|
|10% most volatile stocks in HK Market||13.7%|
|10% least volatile stocks in HK Market||3.3%|
Stable Share Price: 2269 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: 2269's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People’s Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
WuXi Biologics (Cayman) Fundamentals Summary
|2269 fundamental statistics|
Is 2269 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|2269 income statement (TTM)|
|Cost of Revenue||CN¥5.49b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.80|
|Net Profit Margin||32.93%|
How did 2269 perform over the long term?See historical performance and comparison
Is 2269 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2269?
Other financial metrics that can be useful for relative valuation.
|What is 2269's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 2269's PE Ratio compare to its peers?
|2269 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
1521 Frontage Holdings
1873 Viva Biotech Holdings
6118 Austar Lifesciences
A207940 Samsung BiologicsLtd
2269 WuXi Biologics (Cayman)
Price-To-Earnings vs Peers: 2269 is expensive based on its Price-To-Earnings Ratio (76.4x) compared to the peer average (45x).
Price to Earnings Ratio vs Industry
How does 2269's PE Ratio compare vs other companies in the Asian Life Sciences Industry?
Price-To-Earnings vs Industry: 2269 is expensive based on its Price-To-Earnings Ratio (76.4x) compared to the Hong Kong Life Sciences industry average (15.4x)
Price to Earnings Ratio vs Fair Ratio
What is 2269's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||76.4x|
|Fair PE Ratio||25.4x|
Price-To-Earnings vs Fair Ratio: 2269 is expensive based on its Price-To-Earnings Ratio (76.4x) compared to the estimated Fair Price-To-Earnings Ratio (25.4x).
Share Price vs Fair Value
What is the Fair Price of 2269 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 2269 (HK$71.8) is trading below our estimate of fair value (HK$93.35)
Significantly Below Fair Value: 2269 is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: 2269 is poor value based on its PEG Ratio (3.3x)
Discover undervalued companies
How is WuXi Biologics (Cayman) forecast to perform in the next 1 to 3 years based on estimates from 27 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2269's forecast earnings growth (23.4% per year) is above the savings rate (1.6%).
Earnings vs Market: 2269's earnings (23.4% per year) are forecast to grow faster than the Hong Kong market (16.5% per year).
High Growth Earnings: 2269's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 2269's revenue (23.8% per year) is forecast to grow faster than the Hong Kong market (10.1% per year).
High Growth Revenue: 2269's revenue (23.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2269's Return on Equity is forecast to be low in 3 years time (17.3%).
Discover growth companies
How has WuXi Biologics (Cayman) performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2269 has a high level of non-cash earnings.
Growing Profit Margin: 2269's current net profit margins (32.9%) are higher than last year (30.1%).
Past Earnings Growth Analysis
Earnings Trend: 2269's earnings have grown significantly by 53.8% per year over the past 5 years.
Accelerating Growth: 2269's earnings growth over the past year (100.6%) exceeds its 5-year average (53.8% per year).
Earnings vs Industry: 2269 earnings growth over the past year (100.6%) exceeded the Life Sciences industry 45.8%.
Return on Equity
High ROE: 2269's Return on Equity (10.7%) is considered low.
Discover strong past performing companies
How is WuXi Biologics (Cayman)'s financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 2269's short term assets (CN¥19.5B) exceed its short term liabilities (CN¥8.3B).
Long Term Liabilities: 2269's short term assets (CN¥19.5B) exceed its long term liabilities (CN¥3.1B).
Debt to Equity History and Analysis
Debt Level: 2269 has more cash than its total debt.
Reducing Debt: 2269's debt to equity ratio has reduced from 351.5% to 8.4% over the past 5 years.
Debt Coverage: 2269's debt is well covered by operating cash flow (124.2%).
Interest Coverage: 2269 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is WuXi Biologics (Cayman) current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2269's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2269's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2269's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2269's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 2269 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chris Chen (49 yo)
Dr. Zhisheng Chen, also known as Chris, has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr. Chen i...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD7.58M) is above average for companies of similar size in the Hong Kong market ($USD1.06M).
Compensation vs Earnings: Chris's compensation has increased by more than 20% in the past year.
Experienced Management: 2269's management team is considered experienced (4.1 years average tenure).
Experienced Board: 2269's board of directors are considered experienced (5.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 2269 insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
WuXi Biologics (Cayman) Inc.'s employee growth, exchange listings and data sources
- Name: WuXi Biologics (Cayman) Inc.
- Ticker: 2269
- Exchange: SZSC
- Founded: 2014
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$302.946b
- Shares outstanding: 4.22b
- Website: https://www.wuxibiologics.com
Number of Employees
- WuXi Biologics (Cayman) Inc.
- No. 108, Meiliang Road
- Jiangsu Province
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/04 00:00|
|End of Day Share Price||2022/06/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.